Stocks with strongest contrarian momentum

Show me stocks with the strongest contrarian momentum

{"response_type": "stock_research", "acknowledgement": "Here's a list of stocks showing strong contrarian momentum.", "answer": "**Top stocks with the strongest contrarian momentum:**\n\n- **SLXN** (SILEXION THERAPEUTICS CORP): Micro cap, healthcare sector, upside potential +144.3%\n- **MSS** (MAISON SOLUTIONS INC): Micro cap, consumer defensive sector, upside +114.2%\n- **NIVF** (NEWGENIVF GROUP LTD): Micro cap, healthcare sector, upside +72.4%\n- **ENLV** (ENLIVEX LTD): Micro cap, healthcare sector, upside +49.6%\n- **BGL** (BLUE GOLD LTD): Mid cap, basic materials sector, upside +46.6%\n- **JTAI** (JETAI INC): Micro cap, technology sector, upside +46.1%\n- **VNRX** (VOLITIONRX LTD): Micro cap, healthcare sector, upside +36.4%\n\nThese stocks are exhibiting notable contrarian momentum, often in overlooked sectors like healthcare and micro caps, with substantial upside potential based on recent rankings.\n\n**Potential opportunities:** Many of these stocks are in sectors that are typically out of favor (healthcare, basic materials) yet are showing contrarian strength.\n\n**Risks to consider:** Micro caps and CCC-rated stocks carry higher volatility and default risk, so due diligence is essential.\n\nMarkets are closed today. The latest available session (the most recent market close) provides the data on these stocks' rankings and upside potential. Would you like to analyze a specific stock in more detail or see how these fit within your portfolio? Or compare these with sector leaders?", "interpretation": "The stocks listed are exhibiting high upside potential despite their contrarian status, often in sectors like healthcare and materials that may be temporarily out of favor. This suggests a possible mean-reversion or capitulation move, but higher risk is inherent given their ratings and market cap sizes. Next, it\u2019s worth assessing if these stocks align with your risk tolerance and investment horizon.", "hypothesis": {"text": "Contrarian momentum in these stocks is driven by market overreactions to sector-specific concerns, creating valuations attractive for mean reversion.", "confidence": "Moderate"}, "insights": ["Contrarian stocks often in overlooked sectors like healthcare and basic materials.", "Many stocks have low credit ratings, indicating higher default risk but also higher upside potential."], "suggested_questions": ["Check the latest news on SLXN", "Compare MSS and JTAI fundamentals", "View healthcare sector opportunities"], "charts": [{"type": "bar", "title": "Contrarian Momentum Top Stocks - Upside Potential (%)", "data": [{"label": "SLXN", "value": 144.3}, {"label": "MSS", "value": 114.2}, {"label": "NIVF", "value": 72.4}, {"label": "ENLV", "value": 49.6}, {"label": "BGL", "value": 46.6}, {"label": "JTAI", "value": 46.1}, {"label": "VNRX", "value": 36.4}]}], "actions": [], "supporting_data": [{"label": "Rank: SLXN", "value": "upside_avg=144.34883720930233", "source": "metrics"}, {"label": "Rank: MSS", "value": "upside_avg=114.24822695035462", "source": "metrics"}, {"label": "Rank: NIVF", "value": "upside_avg=72.35064935064935", "source": "metrics"}, {"label": "Rank: ENLV", "value": "upside_avg=49.63291139240506", "source": "metrics"}, {"label": "Rank: BGL", "value": "upside_avg=46.61904761904761", "source": "metrics"}], "risk_watch": "", "structured_data": null}

Check the latest news on SLXN

{"response_type": "market_analysis", "acknowledgement": "Here's the latest news on SLXN.", "answer": "**Recent key news for SLXN (Silexion Therapeutics Corp):**\n\n- **Silexion Therapeutics Q2 EPS $(5.17) Misses $(2.12) Estimate** *(Benzinga, Aug 14 09:02)*: SLXN reported a quarterly loss per share of $(5.17), missing analyst consensus estimate of $(2.12). This represents a significant miss, with the loss being approximately 143.87% higher than the estimate. The reported loss also increased compared to the previous quarter.\n- Additional news sources captured general stock movement comments around August 12 but no further specific SLXN headlines.\n\nThe large EPS miss and increased losses are negative fundamental signals for SLXN in the near term.", "interpretation": "SLXN's significant EPS miss and increased losses align with its microcap, higher-risk credit profile, contributing to the recent stock movement. Monitoring future earnings and management commentary will be critical to assess if the trend can reverse or if risk remains elevated.", "hypothesis": {"text": "The poor quarterly earnings result may reinforce negative sentiment, potentially suppressing momentum, though some investors might see contrarian opportunities.", "confidence": "Moderate"}, "insights": ["SLXN's Q2 EPS loss widened further, missing estimates by a wide margin.", "No recent positive news to offset the earnings miss in this period."], "suggested_questions": ["Analyze SLXN's Q2 earnings call transcript", "Compare SLXN with healthcare peers", "Check SLXN credit rating and financial health"], "actions": [{"label": "Analyze SLXN Q2 earnings transcript", "action_type": "earnings_transcript_search", "parameters": {"ticker": "SLXN"}}, {"label": "Compare SLXN with healthcare peers", "action_type": "compare_stocks", "parameters": {"tickers": ["SLXN"]}}, {"label": "Check SLXN credit rating and financial health", "action_type": "web_search", "parameters": {"query": "SLXN credit rating financials 2026"}}], "charts": [], "supporting_data": [], "risk_watch": "", "structured_data": null}

Analyze SLXN's Q2 earnings call transcript

{"response_type": "stock_research", "acknowledgement": "I found the latest Q2 earnings call transcript link for SLXN.", "answer": "**Silexion Therapeutics Corp (SLXN) Q2 Earnings Call Transcript:**\n\n- The transcript for the Q2 2026 earnings call is available from the earnings call link dated around May 15, 2026.\n- Detailed discussions about financial performance, management commentary, and outlook can be reviewed at: [SLXN Earnings Calls](https://finance.yahoo.com/quote/SLXN/earnings-calls/)\n\nUnfortunately, I do not have a direct full transcript text here, but the resource provides comprehensive coverage including analyses and summaries.\n\n*Note:* The earnings data for the quarter ending around May 15, 2026, indicates Silexion reported a significant loss of $(5.17) per share, which missed the analyst estimate of $(2.12) by approximately 143.87%. This represents an increase in losses compared to the previous quarter's losses of $(43.20) per share. For full details, please review the provided earnings call transcript link and related news articles.", "interpretation": "Reviewing the earnings call transcript and management remarks will be key to understanding the drivers behind the heavy EPS miss and loss increase. It can also clarify management\u2019s outlook and any potential recovery catalysts or risks to watch.", "suggested_questions": ["Summarize SLXN Q2 earnings guidance", "Check analyst estimates changes for SLXN", "Compare SLXN financials with peers"], "actions": [{"label": "Search SLXN earnings guidance", "action_type": "search_earnings_guidance", "parameters": {"ticker": "SLXN", "num_quarters": 1}}], "charts": [], "hypothesis": null, "insights": [], "supporting_data": [], "risk_watch": "", "structured_data": null}

Check analyst estimates changes for SLXN

{"response_type": "stock_research", "acknowledgement": "Here's the recent update on analyst estimates for SLXN.", "answer": "**Analyst estimates for SLXN (Silexion Therapeutics Corp):**\n\n- Current quarter (Q2 2026): Estimated EPS is -$2.12, based on a single analyst estimate, with no change from previous estimates.\n- Next quarter (Q3 2026): Analysts project an EPS of -$1.52, representing a positive revision from the current estimate, with growth approximately 94.7% from the same quarter last year.\n- Full-year estimate (2026): EPS forecast is -$5.31, based on a single analyst, indicating ongoing losses.\n- Next year's outlook (2027): Analysts expect EPS around -$18.52, with two analysts providing estimates, reflecting high uncertainty and continued losses.\n\nRevenue estimates are not available or have not been updated recently.\n\nOverall, analyst estimates suggest a slight improvement in the near-term earnings projections, but losses remain substantial, and long-term outlook remains highly negative.", "interpretation": "The estimates show minimal change in EPS projections, with some positive revisions for the upcoming quarter compared to the current estimate. However, the long-term outlook appears highly negative, consistent with SLXN's recent financial challenges. Investors should weigh the potential for short-term improvement against persistent losses and execution risks.", "suggested_questions": ["Compare SLXN's earnings revisions with peers", "Check SLXN's management comments on outlook", "Review recent research reports on SLXN"], "actions": [{"label": "Compare SLXN with healthcare peers", "action_type": "compare_stocks", "parameters": {"tickers": ["SLXN"]}}, {"label": "Check SLXN recent news and analyst reports", "action_type": "web_search", "parameters": {"query": "SLXN analyst reports recent updates"}}], "charts": [], "hypothesis": null, "insights": [], "supporting_data": [], "risk_watch": "", "structured_data": null}